Delft Instruments (the Netherlands) profits stride ahead:
This article was originally published in Clinica
Executive Summary
Delft Instruments (the Netherlands) has reported net profits of Fl 6.9 million ($4.3 million) in 1994, compared with just Fl 0.1 million in 1993. Turnover rose 17% to Fl 453 million, heavily boosted by the acquisition during the year of Dutch cancer therapy company Nucletron (see Clinica No 624, p 12). Delft says 87% of turnover was outside the Netherlands, with fastest growth in the Far East. The medical sector accounted for 58% of sales. The company expects turnover to reach Fl 500 million in 1995 with a widening of profit margins.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.